Holen Sie sich die Stockscreener-App
73.40
1.90%
-1.42
Handel nachbörslich:
73.15
-0.25
-0.34%
Schlusskurs vom Vortag:
$74.82
Offen:
$74.82
24-Stunden-Volumen:
2.76M
Relative Volume:
1.27
Marktkapitalisierung:
$8.59M
Einnahmen:
$947.36M
Nettoeinkommen (Verlust:
$392.47M
KGV:
24.30
EPS:
3.02
Netto-Cashflow:
$392.71M
1W Leistung:
+0.81%
1M Leistung:
+22.35%
6M Leistung:
+26.25%
1J Leistung:
+18.14%
1-Tages-Spanne:
$73.01
$75.46
1-Wochen-Bereich:
$71.50
$75.46
52-Wochen-Spanne:
$42.01
$75.46
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Firmenname
Halozyme Therapeutics Inc
Sektor
Branche
Telefon
(858) 794-8889
Adresse
12390 EL CAMINO REAL, SAN DIEGO, CA
Vergleichen Sie HALO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
73.40 | 8.58B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-06 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2025-05-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Herabstufung | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-06-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | Eingeleitet | TD Cowen | Outperform |
| 2023-07-24 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-05-10 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Fortgesetzt | Berenberg | Buy |
| 2023-03-16 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-11-28 | Eingeleitet | Wells Fargo | Overweight |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-14 | Eingeleitet | Evercore ISI | Outperform |
| 2021-05-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-05-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | Bestätigt | The Benchmark Company | Buy |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-07-01 | Eingeleitet | The Benchmark Company | Buy |
| 2020-02-05 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2018-10-19 | Fortgesetzt | Piper Jaffray | Neutral |
| 2018-05-11 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-01-24 | Eingeleitet | Goldman | Neutral |
| 2017-10-16 | Bestätigt | Piper Jaffray | Overweight |
| 2017-01-06 | Herabstufung | Citigroup | Buy → Neutral |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2015-12-04 | Eingeleitet | Wells Fargo | Outperform |
| 2015-11-18 | Eingeleitet | Citigroup | Buy |
| 2015-09-22 | Eingeleitet | Barclays | Overweight |
| 2015-06-22 | Bestätigt | JP Morgan | Overweight |
| 2015-03-03 | Bestätigt | UBS | Buy |
| 2015-02-18 | Bestätigt | MLV & Co | Buy |
| 2015-01-08 | Bestätigt | MLV & Co | Buy |
Alle ansehen
Halozyme Therapeutics Inc Aktie (HALO) Neueste Nachrichten
Applying Wyckoff theory to Halozyme Therapeutics Inc. stockMarket Volume Report & Accurate Intraday Trade Tips - Newser
Halozyme Therapeutics Inc. recovery potential after sell off2025 Key Lessons & Weekly Top Stock Performers List - Newser
Halozyme Therapeutics (HALO): Revolutionizing Drug Delivery and Scaling Commercial Success - AInvest
Halozyme Therapeutics Presents at Wells Fargo 20th Annual Healthcare Conference 2025: Q&A Session with Helen Torley - AInvest
Halozyme up after guidance raise, Morgan Stanley upgrade - MSN
Transcript : Halozyme Therapeutics, Inc. Presents at Wells Fargo 20th Annual Healthcare Conference 2025, Sep-04-2025 01 - MarketScreener
4 PEG-Rated GARP Stocks That Offer Both Value and Growth - Zacks Investment Research
What to do if you’re stuck in Halozyme Therapeutics Inc.CPI Data & Weekly Setup with High ROI Potential - Newser
Forecasting Halozyme Therapeutics Inc. price range with options dataDip Buying & Free Fast Entry Momentum Trade Alerts - Newser
Leading vs lagging indicators on Halozyme Therapeutics Inc. performance2025 Earnings Surprises & AI Powered Buy and Sell Recommendations - Newser
Will Halozyme Therapeutics Inc. outperform the marketQuarterly Trade Summary & Free Safe Entry Trade Signal Reports - Newser
What to expect from Halozyme Therapeutics Inc. in the next 30 daysPortfolio Gains Summary & Free Community Supported Trade Ideas - Newser
Trend analysis for Halozyme Therapeutics Inc. this weekJuly 2025 Technicals & Safe Capital Growth Plans - Newser
Visual trend scoring systems applied to Halozyme Therapeutics Inc.Weekly Stock Summary & Long-Term Growth Stock Strategies - Newser
Halozyme Therapeutics Inc. stock prediction for this week2025 Breakouts & Breakdowns & Safe Entry Zone Identification - Newser
Are You Looking for a Top Momentum Pick? Why Halozyme Therapeutics (HALO) is a Great Choice - sharewise.com
Connaughton sells Halozyme Therapeutics (HALO) stock worth $294,736 By Investing.com - Investing.com Australia
Halozyme Therapeutics stock reaches all-time high at 74.79 USD - Investing.com
Halozyme Therapeutics and atai Life Sciences N.V. Lead Medical Stocks with 53.4% and 245.1% Year-to-Date Returns Respectively. - AInvest
Best Momentum Stock to Buy for September 3rd - TradingView
Are Medical Stocks Lagging Halozyme Therapeutics (HALO) This Year? - Yahoo Finance
How to Find Strong Buy Medical Stocks Using the Zacks Rank - Yahoo Finance
Halozyme Therapeutics, Inc. (HALO) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Investors Still Aren't Entirely Convinced By Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) Earnings Despite 26% Price Jump - 富途牛牛
New Strong Buy Stocks for September 3rd - The Globe and Mail
Analyzing net buyer seller activity in Halozyme Therapeutics Inc.2025 Analyst Calls & Low Risk High Reward Ideas - Newser
Published on: 2025-09-03 04:54:32 - Newser
Halozyme Therapeutics Inc. stock volume spike explainedTrade Analysis Report & Fast Gain Stock Trading Tips - Newser
Connaughton sells Halozyme Therapeutics (HALO) stock worth $294,736 - Investing.com
What is Halozyme Therapeutics Inc. s P E ratio telling usJuly 2025 PreEarnings & Short-Term High Return Strategies - khodrobank.com
RSI + MACD Show Convergence for Halozyme Therapeutics Inc.Bull Run & Free Expert Verified Stock Movement Alerts - beatles.ru
Earnings Recap: What is Halozyme Therapeutics Inc.’s book value per share - khodrobank.com
Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today - sharewise.com
Can a trend reversal in Halozyme Therapeutics Inc. lead to recoveryQuarterly Earnings Report & Expert Curated Trade Ideas - Newser
Volatility clustering patterns for Halozyme Therapeutics Inc.July 2025 Weekly Recap & Fast Gain Stock Trading Tips - Newser
What’s next for Halozyme Therapeutics Inc. stock priceJuly 2025 Momentum & Community Supported Trade Ideas - Newser
Published on: 2025-09-01 15:56:05 - Newser
Is Halozyme Therapeutics Inc. stock ready for a breakoutQuarterly Portfolio Review & Entry Point Confirmation Signals - Newser
Live Chart Scan Detects Wedge Pattern in Halozyme Therapeutics Inc. getLinesFromResByArray error: size == 0 - 더경남뉴스
A | Can Halozyme Therapeutics, Inc. outperform under higher oil prices - khodrobank.com
What candlestick patterns are forming on Halozyme Therapeutics Inc.July 2025 Review & Consistent Income Trade Ideas - Newser
Published on: 2025-08-31 22:36:40 - beatles.ru
Trendlines Suggest Halozyme Therapeutics Inc. May Bottom Out SoonQuarterly Market Review & Long Hold Capital Preservation Tips - beatles.ru
Real time social sentiment graph for Halozyme Therapeutics Inc.CEO Change & Long-Term Capital Growth Strategies - Newser
Applying big data sentiment scoring on Halozyme Therapeutics Inc.Bear Alert & Weekly High Potential Stock Alerts - Newser
Halozyme Therapeutics, Inc. (HALO) Hikes 2025 Guidance on ENHANZE Demand - MSN
What moving averages say about Halozyme Therapeutics Inc.Weekly Gains Summary & Verified Technical Signals - Newser
Finanzdaten der Halozyme Therapeutics Inc-Aktie (HALO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):